Mydecine Innovations Group Inc. (NEO: MYCO.NE) Stock Competitors & Peer Comparison
See MYCO.NE's competitors and their performance on the NEO and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MYCO.NE and its NEO peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MYCO.NE | CA$0.35 | +0.00% | 21.4M | -0.54 | -CA$0.65 | N/A |
| APTX.TO | CA$33.02 | -2.51% | 7.6B | 20.58 | CA$1.61 | N/A |
| CURA.CN | CA$5.22 | +9.21% | 4.1B | -6.07 | -CA$0.86 | N/A |
| BHC.TO | CA$9.02 | +2.27% | 3.5B | 2.50 | CA$3.69 | N/A |
| CURA.TO | CA$13.40 | -2.40% | 3.1B | 49.46 | CA$0.27 | N/A |
| TRUL.CN | CA$16.14 | -11.07% | 2.7B | -29.01 | -CA$0.56 | N/A |
| GTII.CN | CA$10.42 | -1.23% | 2.4B | 13.97 | CA$0.75 | N/A |
| VRNO.CN | CA$6.32 | +6.76% | 2.2B | -5.40 | -CA$1.17 | N/A |
| CRON.TO | CA$4.84 | +5.57% | 1.8B | 118.59 | CA$0.04 | N/A |
| GUD.TO | CA$9.83 | +1.76% | 948.4M | 64.17 | CA$0.15 | N/A |
Stock Comparison
Apotex Health Corp. (TSX: APTX.TO)
MYCO.NE vs APTX.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, APTX.TO has a market cap of 7.6B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while APTX.TO trades at CA$33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas APTX.TO's P/E ratio is 20.58. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to APTX.TO's ROE of -2.80%. Regarding short-term risk, MYCO.NE is less volatile compared to APTX.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check APTX.TO's competition here
Curaleaf Holdings, Inc. (CNQ: CURA.CN)
MYCO.NE vs CURA.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CURA.CN trades at CA$5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CURA.CN's ROE of -0.13%. Regarding short-term risk, MYCO.NE is less volatile compared to CURA.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CURA.CN's competition here
Bausch Health Companies Inc. (TSX: BHC.TO)
MYCO.NE vs BHC.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BHC.TO has a market cap of 3.5B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BHC.TO trades at CA$9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BHC.TO's P/E ratio is 2.50. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BHC.TO's ROE of +0.88%. Regarding short-term risk, MYCO.NE is less volatile compared to BHC.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check BHC.TO's competition here
Curaleaf Holdings, Inc. (TSX: CURA.TO)
MYCO.NE vs CURA.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CURA.TO has a market cap of 3.1B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CURA.TO trades at CA$13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CURA.TO's P/E ratio is 49.46. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CURA.TO's ROE of -0.05%. Regarding short-term risk, MYCO.NE is less volatile compared to CURA.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CURA.TO's competition here
Trulieve Cannabis Corp. (CNQ: TRUL.CN)
MYCO.NE vs TRUL.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TRUL.CN has a market cap of 2.7B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TRUL.CN trades at CA$16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TRUL.CN's P/E ratio is -29.01. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TRUL.CN's ROE of -0.07%. Regarding short-term risk, MYCO.NE is less volatile compared to TRUL.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TRUL.CN's competition here
Green Thumb Industries Inc. (CNQ: GTII.CN)
MYCO.NE vs GTII.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GTII.CN has a market cap of 2.4B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while GTII.CN trades at CA$10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GTII.CN's P/E ratio is 13.97. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to GTII.CN's ROE of +0.07%. Regarding short-term risk, MYCO.NE is less volatile compared to GTII.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check GTII.CN's competition here
Verano Holdings Corp. (CNQ: VRNO.CN)
MYCO.NE vs VRNO.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VRNO.CN has a market cap of 2.2B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while VRNO.CN trades at CA$6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VRNO.CN's P/E ratio is -5.40. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to VRNO.CN's ROE of -0.03%. Regarding short-term risk, MYCO.NE is less volatile compared to VRNO.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check VRNO.CN's competition here
Cronos Group Inc. (TSX: CRON.TO)
MYCO.NE vs CRON.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CRON.TO has a market cap of 1.8B. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CRON.TO trades at CA$4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CRON.TO's P/E ratio is 118.59. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CRON.TO's ROE of +0.06%. Regarding short-term risk, MYCO.NE is less volatile compared to CRON.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CRON.TO's competition here
Knight Therapeutics Inc. (TSX: GUD.TO)
MYCO.NE vs GUD.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GUD.TO has a market cap of 948.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while GUD.TO trades at CA$9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GUD.TO's P/E ratio is 64.17. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to GUD.TO's ROE of +0.02%. Regarding short-term risk, MYCO.NE is less volatile compared to GUD.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check GUD.TO's competition here
TerrAscend Corp. (CNQ: TER.CN)
MYCO.NE vs TER.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TER.CN has a market cap of 804.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TER.CN trades at CA$2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TER.CN's P/E ratio is -1.33. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TER.CN's ROE of -0.44%. Regarding short-term risk, MYCO.NE is less volatile compared to TER.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TER.CN's competition here
Tilray Brands, Inc. (TSX: TLRY.TO)
MYCO.NE vs TLRY.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TLRY.TO has a market cap of 735.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TLRY.TO trades at CA$6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TLRY.TO's P/E ratio is -4.46. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TLRY.TO's ROE of -0.09%. Regarding short-term risk, MYCO.NE is less volatile compared to TLRY.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TLRY.TO's competition here
Verano Holdings Corp. (NEO: VRNO.NE)
MYCO.NE vs VRNO.NE Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VRNO.NE has a market cap of 613.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while VRNO.NE trades at CA$8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VRNO.NE's P/E ratio is -1.70. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to VRNO.NE's ROE of -0.35%. Regarding short-term risk, MYCO.NE is less volatile compared to VRNO.NE. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check VRNO.NE's competition here
Columbia Care Inc. (NEO: CCHW.NE)
MYCO.NE vs CCHW.NE Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CCHW.NE has a market cap of 407.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CCHW.NE trades at CA$1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CCHW.NE's P/E ratio is -3.52. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CCHW.NE's ROE of -1.07%. Regarding short-term risk, MYCO.NE is less volatile compared to CCHW.NE. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CCHW.NE's competition here
Cresco Labs Inc. (CNQ: CL.CN)
MYCO.NE vs CL.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CL.CN has a market cap of 382.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CL.CN trades at CA$1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CL.CN's P/E ratio is -2.66. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CL.CN's ROE of -0.28%. Regarding short-term risk, MYCO.NE is less volatile compared to CL.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CL.CN's competition here
Cipher Pharmaceuticals Inc. (TSX: CPH.TO)
MYCO.NE vs CPH.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CPH.TO has a market cap of 358M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CPH.TO trades at CA$14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CPH.TO's P/E ratio is 9.17. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CPH.TO's ROE of +0.23%. Regarding short-term risk, MYCO.NE is less volatile compared to CPH.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CPH.TO's competition here
Aurora Cannabis Inc. (TSX: ACB.TO)
MYCO.NE vs ACB.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, ACB.TO has a market cap of 338.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while ACB.TO trades at CA$5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas ACB.TO's P/E ratio is -2.82. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to ACB.TO's ROE of -0.05%. Regarding short-term risk, MYCO.NE is less volatile compared to ACB.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check ACB.TO's competition here
Auxly Cannabis Group Inc. (TSX: XLY.TO)
MYCO.NE vs XLY.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, XLY.TO has a market cap of 316.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while XLY.TO trades at CA$3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas XLY.TO's P/E ratio is 9.40. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to XLY.TO's ROE of +0.18%. Regarding short-term risk, MYCO.NE is less volatile compared to XLY.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check XLY.TO's competition here
Cardiol Therapeutics Inc. (TSX: CRDL.TO)
MYCO.NE vs CRDL.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CRDL.TO has a market cap of 297.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CRDL.TO trades at CA$2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CRDL.TO's P/E ratio is -7.66. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CRDL.TO's ROE of -1.80%. Regarding short-term risk, MYCO.NE is less volatile compared to CRDL.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CRDL.TO's competition here
Canopy Growth Corporation (TSX: WEED.TO)
MYCO.NE vs WEED.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, WEED.TO has a market cap of 265.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while WEED.TO trades at CA$1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas WEED.TO's P/E ratio is -2.36. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to WEED.TO's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to WEED.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check WEED.TO's competition here
TerrAscend Corp. (TSX: TSND.TO)
MYCO.NE vs TSND.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TSND.TO has a market cap of 259.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TSND.TO trades at CA$0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TSND.TO's P/E ratio is -3.38. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TSND.TO's ROE of -0.46%. Regarding short-term risk, MYCO.NE is less volatile compared to TSND.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TSND.TO's competition here
Organigram Global Inc. (TSX: OGI.TO)
MYCO.NE vs OGI.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, OGI.TO has a market cap of 236.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while OGI.TO trades at CA$1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas OGI.TO's P/E ratio is -8.92. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to OGI.TO's ROE of +0.22%. Regarding short-term risk, MYCO.NE is less volatile compared to OGI.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check OGI.TO's competition here
Columbia Care Inc. (CNQ: CCHW.CN)
MYCO.NE vs CCHW.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CCHW.CN has a market cap of 228.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CCHW.CN trades at CA$0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CCHW.CN's P/E ratio is -0.41. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CCHW.CN's ROE of -1.07%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CCHW.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CCHW.CN's competition here
Theratechnologies Inc. (TSX: TH.TO)
MYCO.NE vs TH.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TH.TO has a market cap of 205.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TH.TO trades at CA$4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TH.TO's P/E ratio is -17.19. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TH.TO's ROE of +0.17%. Regarding short-term risk, MYCO.NE is less volatile compared to TH.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TH.TO's competition here
Cannara Biotech Inc. (TSX: LOVE.TO)
MYCO.NE vs LOVE.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LOVE.TO has a market cap of 197.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while LOVE.TO trades at CA$2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LOVE.TO's P/E ratio is 17.32. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to LOVE.TO's ROE of +0.09%. Regarding short-term risk, MYCO.NE is less volatile compared to LOVE.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check LOVE.TO's competition here
Grown Rogue International Inc. (CNQ: GRIN.CN)
MYCO.NE vs GRIN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GRIN.CN has a market cap of 165M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while GRIN.CN trades at CA$0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GRIN.CN's P/E ratio is 40.07. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to GRIN.CN's ROE of -0.13%. Regarding short-term risk, MYCO.NE is less volatile compared to GRIN.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check GRIN.CN's competition here
BioHarvest Sciences Inc. (CNQ: BHSC.CN)
MYCO.NE vs BHSC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BHSC.CN has a market cap of 137.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BHSC.CN trades at CA$7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BHSC.CN's P/E ratio is -4.37. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BHSC.CN's ROE of +1.91%. Regarding short-term risk, MYCO.NE is less volatile compared to BHSC.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check BHSC.CN's competition here
Jushi Holdings Inc. (CNQ: JUSH.CN)
MYCO.NE vs JUSH.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, JUSH.CN has a market cap of 129.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while JUSH.CN trades at CA$0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas JUSH.CN's P/E ratio is -1.35. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to JUSH.CN's ROE of +0.53%. Regarding short-term risk, MYCO.NE is less volatile compared to JUSH.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check JUSH.CN's competition here
HLS Therapeutics Inc. (TSX: HLS.TO)
MYCO.NE vs HLS.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, HLS.TO has a market cap of 115.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while HLS.TO trades at CA$3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas HLS.TO's P/E ratio is -10.22. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to HLS.TO's ROE of -0.14%. Regarding short-term risk, MYCO.NE is less volatile compared to HLS.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check HLS.TO's competition here
Goodness Growth Holdings, Inc. (CNQ: GDNS.CN)
MYCO.NE vs GDNS.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GDNS.CN has a market cap of 91M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while GDNS.CN trades at CA$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GDNS.CN's P/E ratio is -2.74. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to GDNS.CN's ROE of -0.13%. Regarding short-term risk, MYCO.NE is similarly volatile compared to GDNS.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check GDNS.CN's competition here
Charlotte's Web Holdings, Inc. (TSX: CWEB.TO)
MYCO.NE vs CWEB.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CWEB.TO has a market cap of 73.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CWEB.TO trades at CA$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CWEB.TO's P/E ratio is -1.58. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CWEB.TO's ROE of -2.84%. Regarding short-term risk, MYCO.NE is less volatile compared to CWEB.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CWEB.TO's competition here
Vext Science, Inc. (CNQ: VEXT.CN)
MYCO.NE vs VEXT.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VEXT.CN has a market cap of 71.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while VEXT.CN trades at CA$0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VEXT.CN's P/E ratio is -2.87. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to VEXT.CN's ROE of -0.25%. Regarding short-term risk, MYCO.NE is less volatile compared to VEXT.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check VEXT.CN's competition here
Planet 13 Holdings Inc. (CNQ: PLTH.CN)
MYCO.NE vs PLTH.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, PLTH.CN has a market cap of 62.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while PLTH.CN trades at CA$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas PLTH.CN's P/E ratio is -0.75. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to PLTH.CN's ROE of -1.32%. Regarding short-term risk, MYCO.NE is less volatile compared to PLTH.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check PLTH.CN's competition here
The Green Organic Dutchman Holdings Ltd. (CNQ: TGOD.CN)
MYCO.NE vs TGOD.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TGOD.CN has a market cap of 62.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TGOD.CN trades at CA$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TGOD.CN's P/E ratio is -3.28. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TGOD.CN's ROE of +0.01%. Regarding short-term risk, MYCO.NE is similarly volatile compared to TGOD.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check TGOD.CN's competition here
Leef Brands Inc. (CNQ: LEEF.CN)
MYCO.NE vs LEEF.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LEEF.CN has a market cap of 58.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while LEEF.CN trades at CA$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LEEF.CN's P/E ratio is -29.69. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to LEEF.CN's ROE of +2.07%. Regarding short-term risk, MYCO.NE is less volatile compared to LEEF.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check LEEF.CN's competition here
Stem Holdings, Inc. (CNQ: STEM.CN)
MYCO.NE vs STEM.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, STEM.CN has a market cap of 53.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while STEM.CN trades at CA$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas STEM.CN's P/E ratio is -0.00. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to STEM.CN's ROE of -2.75%. Regarding short-term risk, MYCO.NE is similarly volatile compared to STEM.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check STEM.CN's competition here
C21 Investments Inc. (CNQ: CXXI.CN)
MYCO.NE vs CXXI.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CXXI.CN has a market cap of 45.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CXXI.CN trades at CA$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CXXI.CN's P/E ratio is -12.74. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CXXI.CN's ROE of -0.17%. Regarding short-term risk, MYCO.NE is less volatile compared to CXXI.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CXXI.CN's competition here
MariMed Inc. (CNQ: MRMD.CN)
MYCO.NE vs MRMD.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MRMD.CN has a market cap of 43.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while MRMD.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MRMD.CN's P/E ratio is -3.91. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to MRMD.CN's ROE of -0.30%. Regarding short-term risk, MYCO.NE is less volatile compared to MRMD.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check MRMD.CN's competition here
BioNxt Solutions Inc. (CNQ: BNXT.CN)
MYCO.NE vs BNXT.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BNXT.CN has a market cap of 43.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BNXT.CN trades at CA$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BNXT.CN's P/E ratio is -6.10. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BNXT.CN's ROE of +1.11%. Regarding short-term risk, MYCO.NE is less volatile compared to BNXT.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check BNXT.CN's competition here
HEXO Corp. (TSX: HEXO.TO)
MYCO.NE vs HEXO.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, HEXO.TO has a market cap of 38.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while HEXO.TO trades at CA$0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas HEXO.TO's P/E ratio is -0.26. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to HEXO.TO's ROE of -2.06%. Regarding short-term risk, MYCO.NE is less volatile compared to HEXO.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check HEXO.TO's competition here
Waverunner Capital Inc. (CNQ: CHM.CN)
MYCO.NE vs CHM.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CHM.CN has a market cap of 37.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CHM.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CHM.CN's P/E ratio is -5.00. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CHM.CN's ROE of +1.16%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CHM.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CHM.CN's competition here
iAnthus Capital Holdings, Inc. (CNQ: IAN.CN)
MYCO.NE vs IAN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, IAN.CN has a market cap of 34.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while IAN.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas IAN.CN's P/E ratio is 7.94. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to IAN.CN's ROE of +0.50%. Regarding short-term risk, MYCO.NE is less volatile compared to IAN.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check IAN.CN's competition here
MediPharm Labs Corp. (TSX: LABS.TO)
MYCO.NE vs LABS.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LABS.TO has a market cap of 31.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while LABS.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LABS.TO's P/E ratio is -3.47. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to LABS.TO's ROE of -0.14%. Regarding short-term risk, MYCO.NE is similarly volatile compared to LABS.TO. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check LABS.TO's competition here
1CM Inc. (CNQ: EPIC.CN)
MYCO.NE vs EPIC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, EPIC.CN has a market cap of 30.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while EPIC.CN trades at CA$0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas EPIC.CN's P/E ratio is 7.08. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to EPIC.CN's ROE of +0.15%. Regarding short-term risk, MYCO.NE is less volatile compared to EPIC.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check EPIC.CN's competition here
MedMen Enterprises Inc. (CNQ: MMEN.CN)
MYCO.NE vs MMEN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MMEN.CN has a market cap of 27.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while MMEN.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MMEN.CN's P/E ratio is -0.13. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to MMEN.CN's ROE of -0.96%. Regarding short-term risk, MYCO.NE is less volatile compared to MMEN.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check MMEN.CN's competition here
Mountain Valley MD Holdings Inc. (CNQ: MVMD.CN)
MYCO.NE vs MVMD.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MVMD.CN has a market cap of 24.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while MVMD.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MVMD.CN's P/E ratio is -4.27. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to MVMD.CN's ROE of -3.14%. Regarding short-term risk, MYCO.NE is less volatile compared to MVMD.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check MVMD.CN's competition here
YourWay Cannabis Brands Inc. (CNQ: YOUR.CN)
MYCO.NE vs YOUR.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, YOUR.CN has a market cap of 22.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while YOUR.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas YOUR.CN's P/E ratio is 8.50. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to YOUR.CN's ROE of -1.18%. Regarding short-term risk, MYCO.NE is similarly volatile compared to YOUR.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check YOUR.CN's competition here
Optimi Health Corp. (CNQ: OPTI.CN)
MYCO.NE vs OPTI.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, OPTI.CN has a market cap of 21.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while OPTI.CN trades at CA$6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas OPTI.CN's P/E ratio is -17.30. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to OPTI.CN's ROE of -0.84%. Regarding short-term risk, MYCO.NE is less volatile compared to OPTI.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check OPTI.CN's competition here
Vinergy Capital Inc. (CNQ: VIN.CN)
MYCO.NE vs VIN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VIN.CN has a market cap of 20.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while VIN.CN trades at CA$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VIN.CN's P/E ratio is -0.67. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to VIN.CN's ROE of -0.79%. Regarding short-term risk, MYCO.NE is not fully comparable compared to VIN.CN. This indicates unavailable risk data in terms of short-term price fluctuations for MYCO.NE.Check VIN.CN's competition here
Captiva Verde Wellness Corp. (CNQ: PWR.CN)
MYCO.NE vs PWR.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, PWR.CN has a market cap of 18.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while PWR.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas PWR.CN's P/E ratio is -15.79. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to PWR.CN's ROE of -0.83%. Regarding short-term risk, MYCO.NE is similarly volatile compared to PWR.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check PWR.CN's competition here
Ayr Wellness Inc. (CNQ: AYR-A.CN)
MYCO.NE vs AYR-A.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AYR-A.CN has a market cap of 18.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AYR-A.CN trades at CA$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AYR-A.CN's P/E ratio is -0.11. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AYR-A.CN's ROE of -0.75%. Regarding short-term risk, MYCO.NE is less volatile compared to AYR-A.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check AYR-A.CN's competition here
Avicanna Inc. (TSX: AVCN.TO)
MYCO.NE vs AVCN.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AVCN.TO has a market cap of 17.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AVCN.TO trades at CA$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AVCN.TO's P/E ratio is -6.33. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AVCN.TO's ROE of -1.08%. Regarding short-term risk, MYCO.NE is similarly volatile compared to AVCN.TO. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check AVCN.TO's competition here
IM Cannabis Corp. (CNQ: IMCC.CN)
MYCO.NE vs IMCC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, IMCC.CN has a market cap of 17.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while IMCC.CN trades at CA$5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas IMCC.CN's P/E ratio is -2.68. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to IMCC.CN's ROE of -0.03%. Regarding short-term risk, MYCO.NE is less volatile compared to IMCC.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check IMCC.CN's competition here
EXMceuticals Inc. (CNQ: EXM.CN)
MYCO.NE vs EXM.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, EXM.CN has a market cap of 15.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while EXM.CN trades at CA$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas EXM.CN's P/E ratio is -0.91. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to EXM.CN's ROE of -18.63%. Regarding short-term risk, MYCO.NE is similarly volatile compared to EXM.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check EXM.CN's competition here
Crescita Therapeutics Inc. (TSX: CTX.TO)
MYCO.NE vs CTX.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CTX.TO has a market cap of 14.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CTX.TO trades at CA$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CTX.TO's P/E ratio is -42.52. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CTX.TO's ROE of -0.02%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CTX.TO. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CTX.TO's competition here
Chalice Brands Ltd. (CNQ: CHAL.CN)
MYCO.NE vs CHAL.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CHAL.CN has a market cap of 14.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CHAL.CN trades at CA$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CHAL.CN's P/E ratio is -2.25. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CHAL.CN's ROE of +0.00%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CHAL.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CHAL.CN's competition here
Red White & Bloom Brands Inc. (CNQ: RWB.CN)
MYCO.NE vs RWB.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RWB.CN has a market cap of 14.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while RWB.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RWB.CN's P/E ratio is -0.16. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to RWB.CN's ROE of +0.43%. Regarding short-term risk, MYCO.NE is similarly volatile compared to RWB.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check RWB.CN's competition here
RIV Capital Inc. (CNQ: RIV.CN)
MYCO.NE vs RIV.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RIV.CN has a market cap of 13.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while RIV.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RIV.CN's P/E ratio is -0.21. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to RIV.CN's ROE of -1.13%. Regarding short-term risk, MYCO.NE is similarly volatile compared to RIV.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check RIV.CN's competition here
Greenway Greenhouse Cannabis Corporation (CNQ: GWAY.CN)
MYCO.NE vs GWAY.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, GWAY.CN has a market cap of 13.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while GWAY.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas GWAY.CN's P/E ratio is -15.38. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to GWAY.CN's ROE of -0.27%. Regarding short-term risk, MYCO.NE is similarly volatile compared to GWAY.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check GWAY.CN's competition here
Red Light Holland Corp. (CNQ: TRIP.CN)
MYCO.NE vs TRIP.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TRIP.CN has a market cap of 12.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TRIP.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TRIP.CN's P/E ratio is -2.80. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TRIP.CN's ROE of -0.41%. Regarding short-term risk, MYCO.NE is less volatile compared to TRIP.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TRIP.CN's competition here
Orion Nutraceuticals Inc. (CNQ: ORI.CN)
MYCO.NE vs ORI.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, ORI.CN has a market cap of 11.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while ORI.CN trades at CA$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas ORI.CN's P/E ratio is -2.11. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to ORI.CN's ROE of +0.07%. Regarding short-term risk, MYCO.NE is similarly volatile compared to ORI.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check ORI.CN's competition here
Revive Therapeutics Ltd. (CNQ: RVV.CN)
MYCO.NE vs RVV.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RVV.CN has a market cap of 10.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while RVV.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RVV.CN's P/E ratio is -17.86. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to RVV.CN's ROE of +2.89%. Regarding short-term risk, MYCO.NE is less volatile compared to RVV.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check RVV.CN's competition here
Avant Brands Inc. (TSX: AVNT.TO)
MYCO.NE vs AVNT.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AVNT.TO has a market cap of 10.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AVNT.TO trades at CA$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AVNT.TO's P/E ratio is -0.71. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AVNT.TO's ROE of -0.50%. Regarding short-term risk, MYCO.NE is less volatile compared to AVNT.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check AVNT.TO's competition here
CanaFarma Hemp Products Corp. (CNQ: CNFA.CN)
MYCO.NE vs CNFA.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CNFA.CN has a market cap of 9.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CNFA.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CNFA.CN's P/E ratio is -0.83. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CNFA.CN's ROE of -7.84%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CNFA.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CNFA.CN's competition here
VIVO Cannabis Inc. (TSX: VIVO.TO)
MYCO.NE vs VIVO.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, VIVO.TO has a market cap of 9.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while VIVO.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas VIVO.TO's P/E ratio is -0.16. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to VIVO.TO's ROE of -0.78%. Regarding short-term risk, MYCO.NE is less volatile compared to VIVO.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check VIVO.TO's competition here
CLS Holdings USA, Inc. (CNQ: CLSH.CN)
MYCO.NE vs CLSH.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CLSH.CN has a market cap of 8.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CLSH.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CLSH.CN's P/E ratio is 3.50. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CLSH.CN's ROE of +0.37%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CLSH.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CLSH.CN's competition here
Aleafia Health Inc. (TSX: AH.TO)
MYCO.NE vs AH.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AH.TO has a market cap of 8.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AH.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AH.TO's P/E ratio is -0.22. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AH.TO's ROE of -0.58%. Regarding short-term risk, MYCO.NE is less volatile compared to AH.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check AH.TO's competition here
Australis Capital Inc. (CNQ: AUSA.CN)
MYCO.NE vs AUSA.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AUSA.CN has a market cap of 7.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AUSA.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AUSA.CN's P/E ratio is -0.32. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AUSA.CN's ROE of -1.15%. Regarding short-term risk, MYCO.NE is similarly volatile compared to AUSA.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check AUSA.CN's competition here
StateHouse Holdings Inc. (CNQ: STHZ.CN)
MYCO.NE vs STHZ.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, STHZ.CN has a market cap of 7.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while STHZ.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas STHZ.CN's P/E ratio is -0.10. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to STHZ.CN's ROE of +0.36%. Regarding short-term risk, MYCO.NE is similarly volatile compared to STHZ.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check STHZ.CN's competition here
Christina Lake Cannabis Corp. (CNQ: CLC.CN)
MYCO.NE vs CLC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CLC.CN has a market cap of 7.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CLC.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CLC.CN's P/E ratio is 12.50. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CLC.CN's ROE of -0.31%. Regarding short-term risk, MYCO.NE is less volatile compared to CLC.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CLC.CN's competition here
Blueberries Medical Corp. (CNQ: BBM.CN)
MYCO.NE vs BBM.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BBM.CN has a market cap of 7.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BBM.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BBM.CN's P/E ratio is -4.95. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BBM.CN's ROE of -1.92%. Regarding short-term risk, MYCO.NE is similarly volatile compared to BBM.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check BBM.CN's competition here
Sproutly Canada Inc. (CNQ: SPR.CN)
MYCO.NE vs SPR.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, SPR.CN has a market cap of 7.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while SPR.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas SPR.CN's P/E ratio is -0.49. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to SPR.CN's ROE of +18.75%. Regarding short-term risk, MYCO.NE is similarly volatile compared to SPR.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check SPR.CN's competition here
Mojave Brands Inc. (CNQ: MOJO.CN)
MYCO.NE vs MOJO.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MOJO.CN has a market cap of 7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while MOJO.CN trades at CA$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MOJO.CN's P/E ratio is -8.45. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to MOJO.CN's ROE of -0.77%. Regarding short-term risk, MYCO.NE is similarly volatile compared to MOJO.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check MOJO.CN's competition here
Nextleaf Solutions Ltd. (CNQ: OILS.CN)
MYCO.NE vs OILS.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, OILS.CN has a market cap of 6.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while OILS.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas OILS.CN's P/E ratio is -4.72. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to OILS.CN's ROE of -0.30%. Regarding short-term risk, MYCO.NE is similarly volatile compared to OILS.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check OILS.CN's competition here
Sweet Earth Holdings Corporation (CNQ: SE.CN)
MYCO.NE vs SE.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, SE.CN has a market cap of 6.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while SE.CN trades at CA$0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas SE.CN's P/E ratio is -0.60. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to SE.CN's ROE of -15.22%. Regarding short-term risk, MYCO.NE is similarly volatile compared to SE.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check SE.CN's competition here
Sunniva Inc. (CNQ: SNN.CN)
MYCO.NE vs SNN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, SNN.CN has a market cap of 6.1M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while SNN.CN trades at CA$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas SNN.CN's P/E ratio is -0.13. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to SNN.CN's ROE of -0.49%. Regarding short-term risk, MYCO.NE is similarly volatile compared to SNN.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check SNN.CN's competition here
CordovaCann Corp. (CNQ: CDVA.CN)
MYCO.NE vs CDVA.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CDVA.CN has a market cap of 5.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CDVA.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CDVA.CN's P/E ratio is -1.09. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CDVA.CN's ROE of +0.44%. Regarding short-term risk, MYCO.NE is less volatile compared to CDVA.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check CDVA.CN's competition here
1933 Industries Inc. (CNQ: TGIF.CN)
MYCO.NE vs TGIF.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TGIF.CN has a market cap of 5.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TGIF.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TGIF.CN's P/E ratio is 4.27. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TGIF.CN's ROE of -0.12%. Regarding short-term risk, MYCO.NE is less volatile compared to TGIF.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check TGIF.CN's competition here
Willow Biosciences Inc. (TSX: WLLW.TO)
MYCO.NE vs WLLW.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, WLLW.TO has a market cap of 5.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while WLLW.TO trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas WLLW.TO's P/E ratio is -0.22. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to WLLW.TO's ROE of +0.00%. Regarding short-term risk, MYCO.NE is less volatile compared to WLLW.TO. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check WLLW.TO's competition here
The BC Bud Corporation (CNQ: BCBC.CN)
MYCO.NE vs BCBC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BCBC.CN has a market cap of 5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BCBC.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BCBC.CN's P/E ratio is -2.00. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BCBC.CN's ROE of -1.93%. Regarding short-term risk, MYCO.NE is less volatile compared to BCBC.CN. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check BCBC.CN's competition here
Heritage Cannabis Holdings Corp. (CNQ: CANN.CN)
MYCO.NE vs CANN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CANN.CN has a market cap of 4.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CANN.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CANN.CN's P/E ratio is -0.22. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CANN.CN's ROE of -0.66%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CANN.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CANN.CN's competition here
Bhang Inc. (CNQ: BHNG.CN)
MYCO.NE vs BHNG.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BHNG.CN has a market cap of 4.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BHNG.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BHNG.CN's P/E ratio is -0.94. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BHNG.CN's ROE of +4.00%. Regarding short-term risk, MYCO.NE is similarly volatile compared to BHNG.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check BHNG.CN's competition here
4Front Ventures Corp. (CNQ: FFNT.CN)
MYCO.NE vs FFNT.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, FFNT.CN has a market cap of 4.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while FFNT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas FFNT.CN's P/E ratio is -0.03. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to FFNT.CN's ROE of +7.89%. Regarding short-term risk, MYCO.NE is similarly volatile compared to FFNT.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check FFNT.CN's competition here
Luff Enterprises Ltd. (CNQ: LUFF.CN)
MYCO.NE vs LUFF.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, LUFF.CN has a market cap of 4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while LUFF.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas LUFF.CN's P/E ratio is -0.56. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to LUFF.CN's ROE of -0.32%. Regarding short-term risk, MYCO.NE is not fully comparable compared to LUFF.CN. This indicates unavailable risk data in terms of short-term price fluctuations for MYCO.NE.Check LUFF.CN's competition here
Filament Health Corp. (NEO: FH.NE)
MYCO.NE vs FH.NE Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, FH.NE has a market cap of 3.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while FH.NE trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas FH.NE's P/E ratio is -0.50. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to FH.NE's ROE of -1.38%. Regarding short-term risk, MYCO.NE is less volatile compared to FH.NE. This indicates lower risk in terms of short-term price fluctuations for MYCO.NE.Check FH.NE's competition here
Body and Mind Inc. (CNQ: BAMM.CN)
MYCO.NE vs BAMM.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, BAMM.CN has a market cap of 3.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while BAMM.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas BAMM.CN's P/E ratio is -0.01. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to BAMM.CN's ROE of +65.27%. Regarding short-term risk, MYCO.NE is similarly volatile compared to BAMM.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check BAMM.CN's competition here
TILT Holdings Inc. (NEO: TILT.NE)
MYCO.NE vs TILT.NE Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, TILT.NE has a market cap of 3.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while TILT.NE trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas TILT.NE's P/E ratio is -0.03. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to TILT.NE's ROE of +0.45%. Regarding short-term risk, MYCO.NE is similarly volatile compared to TILT.NE. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check TILT.NE's competition here
Refined Metals Corp. (CNQ: RMC.CN)
MYCO.NE vs RMC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, RMC.CN has a market cap of 3.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while RMC.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas RMC.CN's P/E ratio is -4.00. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to RMC.CN's ROE of +1.25%. Regarding short-term risk, MYCO.NE is similarly volatile compared to RMC.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check RMC.CN's competition here
THC Biomed Intl Ltd. (CNQ: THC.CN)
MYCO.NE vs THC.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, THC.CN has a market cap of 3.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while THC.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas THC.CN's P/E ratio is -0.89. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to THC.CN's ROE of -0.37%. Regarding short-term risk, MYCO.NE is similarly volatile compared to THC.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check THC.CN's competition here
North Bud Farms Inc. (CNQ: NBUD.CN)
MYCO.NE vs NBUD.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, NBUD.CN has a market cap of 3.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while NBUD.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas NBUD.CN's P/E ratio is -1.25. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to NBUD.CN's ROE of -0.27%. Regarding short-term risk, MYCO.NE is similarly volatile compared to NBUD.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check NBUD.CN's competition here
ManifestSeven Holdings Corporation (CNQ: MSVN.CN)
MYCO.NE vs MSVN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, MSVN.CN has a market cap of 2.9M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while MSVN.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas MSVN.CN's P/E ratio is -0.06. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to MSVN.CN's ROE of +19.42%. Regarding short-term risk, MYCO.NE is similarly volatile compared to MSVN.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check MSVN.CN's competition here
AREV Life Sciences Global Corp. (CNQ: AREV.CN)
MYCO.NE vs AREV.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AREV.CN has a market cap of 2.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AREV.CN trades at CA$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AREV.CN's P/E ratio is -98.90. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AREV.CN's ROE of +2.76%. Regarding short-term risk, MYCO.NE is similarly volatile compared to AREV.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check AREV.CN's competition here
Acerus Pharmaceuticals Corporation (TSX: ASP.TO)
MYCO.NE vs ASP.TO Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, ASP.TO has a market cap of 2.8M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while ASP.TO trades at CA$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas ASP.TO's P/E ratio is -0.08. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to ASP.TO's ROE of +3.10%. Regarding short-term risk, MYCO.NE is similarly volatile compared to ASP.TO. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check ASP.TO's competition here
Craftport Cannabis Corp. (CNQ: CFT.CN)
MYCO.NE vs CFT.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CFT.CN has a market cap of 2.7M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CFT.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CFT.CN's P/E ratio is -0.13. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CFT.CN's ROE of -2.12%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CFT.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CFT.CN's competition here
Isracann Biosciences Inc. (CNQ: IPOT.CN)
MYCO.NE vs IPOT.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, IPOT.CN has a market cap of 2.6M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while IPOT.CN trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas IPOT.CN's P/E ratio is -3.41. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to IPOT.CN's ROE of -2.22%. Regarding short-term risk, MYCO.NE is similarly volatile compared to IPOT.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check IPOT.CN's competition here
Aion Therapeutic Inc. (CNQ: AION.CN)
MYCO.NE vs AION.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, AION.CN has a market cap of 2.5M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while AION.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas AION.CN's P/E ratio is -1.09. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to AION.CN's ROE of +1.91%. Regarding short-term risk, MYCO.NE is similarly volatile compared to AION.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check AION.CN's competition here
Flower One Holdings Inc. (CNQ: FONE.CN)
MYCO.NE vs FONE.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, FONE.CN has a market cap of 2.4M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while FONE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas FONE.CN's P/E ratio is -0.10. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to FONE.CN's ROE of +8.32%. Regarding short-term risk, MYCO.NE is similarly volatile compared to FONE.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check FONE.CN's competition here
Choom Holdings Inc. (CNQ: CHOO.CN)
MYCO.NE vs CHOO.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CHOO.CN has a market cap of 2.3M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CHOO.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CHOO.CN's P/E ratio is -0.10. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CHOO.CN's ROE of +4.09%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CHOO.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CHOO.CN's competition here
West Island Brands Inc. (CNQ: WIB.CN)
MYCO.NE vs WIB.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, WIB.CN has a market cap of 2.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while WIB.CN trades at CA$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas WIB.CN's P/E ratio is -0.39. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to WIB.CN's ROE of -1.00%. Regarding short-term risk, MYCO.NE is similarly volatile compared to WIB.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check WIB.CN's competition here
CBD Global Sciences Inc. (CNQ: CBDN.CN)
MYCO.NE vs CBDN.CN Comparison August 2026
Mydecine Innovations Group Inc. (NEO: MYCO.NE) plays a significant role within the Healthcare sector. Its performance on the NEO reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYCO.NE stands at 21.4M. In comparison, CBDN.CN has a market cap of 2.2M. Regarding current trading prices, MYCO.NE is priced at CA$0.35 on the NEO, while CBDN.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYCO.NE currently has a P/E ratio of -0.54, whereas CBDN.CN's P/E ratio is -0.25. In terms of profitability, MYCO.NE's ROE is +0.02%, compared to CBDN.CN's ROE of +1.16%. Regarding short-term risk, MYCO.NE is similarly volatile compared to CBDN.CN. This indicates similar risk in terms of short-term price fluctuations for MYCO.NE.Check CBDN.CN's competition here